Epidemiological Analysis of Cardiac Mortality Trends in Patients with Amyloidosis
By
Abdalhakim Shubietah
Diana Owda
Mohamed Saad Rakab
Yazan Dawoud
Ahmed Khraiwesh
Mohamed S. Elgendy
Mohammed Tareq Mutar
Ahmed Emara
Ali Saad Al-Shammari
Ameer Awashra
Mohammed AbuBaha
Zaina Nazzal
Bandar Alyami
Ramesh Daggubati
Yasar Sattar
December 30, 2025
Clinical Scorecard: Epidemiological Analysis of Cardiac Mortality Trends in Patients with Amyloidosis
At a Glance
Category Detail
Condition Cardiac Amyloidosis Key Mechanisms Involves light-chain (AL) and transthyretin (ATTR) subtypes affecting cardiovascular health. Target Population U.S. decedents aged ≥ 25 years with amyloidosis. Care Setting Nationwide observational study using CDC WONDER database.
Key Highlights
Significant contributor to cardiovascular morbidity and mortality. Improved recognition with advanced imaging modalities. Introduction of disease-modifying agents like tafamidis and daratumumab. Utilization of age-adjusted mortality rates for valid comparisons. Machine learning techniques forecast future mortality trends. Guideline-Based Recommendations
Diagnosis
Utilize advanced imaging modalities such as technetium-labeled scintigraphy and cardiac MRI. Management
Consider disease-modifying agents like tafamidis for ATTR-CM and daratumumab for AL amyloidosis. Monitoring & Follow-up
Employ age-adjusted mortality rates (AAMRs) for tracking trends. Risks
Cardiac involvement defined by multiple-cause-of-death codes related to cardiac conditions. Patient & Prescribing Data
Patients with amyloidosis aged ≥ 25 years.
Improved clinical outcomes with new therapeutic agents.
Clinical Best Practices
Conduct comprehensive epidemiological surveillance for cardiac amyloidosis. Stratify mortality data by demographic factors for better insights. Utilize Joinpoint regression analysis for trend detection. References
